The $7 Billion Nicotine-Pouch Market's Next Target? Women
At Odenplan Square in central Stockholm, high school students move in packs, enjoying a day off and the early spring weather. Even though graduation is still weeks away, some seniors are already sporting their celebratory caps, per Swedish tradition. One of them is 19-year-old Olivia Persson, who, in addition to wearing the sailor-style hat, carries a bright tin of nicotine pouches. So do most of the other girls in her crew, each in turn showing off colorful containers with peach and apple-mint flavors tucked into pockets and purses.
'It's just fun,' Persson says of the Chiclet-size packets, or tobacco-free snus, that users tuck between their gums and lips for a quick hit of nicotine. 'You feel more alert, and everyone does it, so it's easy to think, 'How bad can it be?' '
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 hours ago
- Yahoo
Alligator Bioscience Receives FDA Endorsement of Mitazalimab Phase 3 Dose for Pancreatic Cancer
LUND, SE / / June 13, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has provided feedback supporting the selection of the 900 µg/kg dose of its CD40 agonist mitazalimab for the planned Phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC). This positive regulatory feedback confirms Alligator's dose selection and represents a key milestone in the late-stage development of mitazalimab. "We are very pleased with the FDA's timely and constructive response. This marks an important step forward as we finalize our Phase 3 program for mitazalimab in one of the most aggressive and underserved cancers. We are now in active partnering dialogues aiming to secure the right partner to take mitazalimab into Phase 3," said Søren Bregenholt, CEO of Alligator Bioscience . For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 8:45 a.m. CEST on 13 June 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit . Attachments Alligator Bioscience receives FDA endorsement of mitazalimab Phase 3 dose for pancreatic cancer SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
2 days ago
- Bloomberg
The $7 Billion Nicotine-Pouch Market's Next Target? Women
At Odenplan Square in central Stockholm, high school students move in packs, enjoying a day off and the early spring weather. Even though graduation is still weeks away, some seniors are already sporting their celebratory caps, per Swedish tradition. One of them is 19-year-old Olivia Persson, who, in addition to wearing the sailor-style hat, carries a bright tin of nicotine pouches. So do most of the other girls in her crew, each in turn showing off colorful containers with peach and apple-mint flavors tucked into pockets and purses. 'It's just fun,' Persson says of the Chiclet-size packets, or tobacco-free snus, that users tuck between their gums and lips for a quick hit of nicotine. 'You feel more alert, and everyone does it, so it's easy to think, 'How bad can it be?' '
Yahoo
2 days ago
- Yahoo
Elekta appoints Jakob Just-Bomholt as CEO
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Name: Jakob Just-Bomholt New title: CEO, Elekta Previous title: CEO, 3Shape Elekta has appointed Jakob Just-Bomholt as president and CEO. Just-Bomholt will take up the positions on Sept. 1, filling a vacancy created in March when the cancer radiotherapy company's board decided a new leader was needed to improve profitability and growth. Stockholm-based Elekta competes with Siemens Healthineers' Varian in the radiotherapy market. Elekta is looking to its new Evo radiation therapy machine to strengthen its position. However, while the device is on the market in Europe, helping drive 3% global sales growth in the most recent quarter, Elekta has yet to launch Evo in the U.S. The company has said U.S. customers are waiting for Evo, suppressing sales. Just-Bomholt will oversee Elekta's attempt to recover in the U.S. and in China, where sales have been hit by the anti-corruption drive, and build on momentum in Europe. The executive stepped down as CEO of 3Shape, a Danish digital dental scanning firm, earlier this year. The privately held 3Shape said in a statement at the time that Just-Bomholt spent 'five successful years' as CEO. Laurent Leksell, Elekta's founder and chairman, said in a statement that Just-Bomholt is well-suited to his new role. Leksell cited Just-Bomholt's strategic leadership, international experience and ability to drive profitable growth and global expansion as evidence he is the right person for the job. Just-Bomholt is set to begin onboarding in August, working with interim CEO Jonas Bolander to transition into the CEO post on Sept. 1. Bolander has spent his time as interim CEO 'stabilizing and simplifying the business,' the executive said on an earnings call late last month, and oversaw a change in Elekta's plans for bringing Evo to the U.S. market. Elekta withdrew its filing for clearance of Evo, and as of the May 28 earnings call, was in the process of resubmitting its application. Bolander said the change in filing strategy is intended to better align with the Food and Drug Administration's approval process, with a greater focus on cybersecurity. The interim CEO expects the delay to have a 'limited' impact on the overall product launch. Recommended Reading Elekta CEO Gustaf Salford to leave after board sees need for new leader Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
